Tarsus Pharmaceuticals, Inc. (TARS): Free Cash Flow
-$22.31M
Year ended 2025-12-31
$56.00M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | -$22.31M | n/m | 2026-02-23, From 2025-01-01 |
| 2024-12-31 | -$84.59M | n/m | 2026-02-23, From 2024-01-01 |
| 2023-12-31 | -$119.00M | n/m | 2026-02-23, From 2023-01-01 |
| 2022-12-31 | -$49.54M | n/m | 2025-02-25, From 2022-01-01 |
| 2021-12-31 | $3.16M | n/m | 2023-03-17, From 2021-01-01 |
| 2020-12-31 | -$21.59M | n/m | 2022-03-14, From 2020-01-01 |
| 2019-12-31 | -$3.85M | n/a | 2021-03-31, From 2019-01-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | 2025-12-31 | -$22.31M | n/m |
| Immunocore Holdings plc (IMCR) | 2025-12-31 | -$15.05M | n/m |
| ADMA Biologics, Inc. (ADMA) | 2025-12-31 | $27.82M | -74.8% |
| Krystal Biotech, Inc. (KRYS) | 2025-12-31 | $188.91M | +58.5% |
| Twist Bioscience Corp (TWST) | 2025-09-30 | -$75.63M | n/m |
| Adaptive Biotechnologies Corp (ADPT) | 2025-12-31 | -$48.95M | n/m |
| Vericel Corp (VCEL) | 2025-12-31 | $24.75M | n/m |
| Repligen Corp (RGEN) | 2025-12-31 | $93.90M | -37.3% |
| Iovance Biotherapeutics, Inc. (IOVA) | 2025-12-31 | -$336.24M | n/m |
Compare TARS, IMCR, ADMA, KRYS side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗